Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: A vent system for use during respiratory therapy with a flow of pressurized gas may provide a continuous vent flow of gas. The vent system may include a vent housing having an outer wall; an inner wall, the inner wall defining an inlet for the flow of gas; and a base positioned between the outer wall and the inner wall, the base having at least one first orifice and at least one second orifice. The vent system may include a membrane, the membrane being shaped and dimensioned such that the membrane does not cover the at least one first orifice to allow the vent flow through the at least one first orifice, and the membrane being shaped and dimensioned such that in a first position the membrane is positioned over the at least one second orifice to allow the vent flow through the at least one second orifice.

Abstract: A method of measuring the amount of energy consumed from a water heater having a tank with two or more temperature sensors located a predetermined heights on or in the tank, the method including the step of; for each sensor, determining a corresponding volume of a segment of the tank, measuring the change of temperature at each temperature sensor, calculating the energy for the corresponding volume for each sensor, and summing the energy changes for all the sensors to determine the amount of energy consumed. The energy usage can be recorded with chronological information to construct a usage pattern which can be used for controlling the heater and for providing the user with details of energy usage. The system does not require the use of data derived from a flow meter.

Abstract: A patient interface includes a cushion assembly adapted to form a seal around the patient's nose and/or mouth and a gas washout vent configured to allow a flow of patient exhaled CO2 to an exterior of the patient interface to minimise rebreathing of exhaled CO2 by the patient. The cushion assembly defines a plenum chamber pressurised at a pressure above ambient pressure in use. At least one volume reducing member is provided within the plenum chamber to reduce an effective internal volume of the plenum chamber. The at least one volume reducing member is arranged to separate a main volume of the plenum chamber for delivery of the therapy pressure from deadspace volume provided at least superior the entrance to the patient's nasal passages. The main volume is adapted to be in direct fluid communication with the patient's nose and/or mouth and the vent.

Abstract: A method of measuring the amount of energy consumed from a water heater having a tank with two or more temperature sensors located a predetermined heights on or in the tank, the method including the step of; for each sensor, determining a corresponding volume of a segment of the tank, measuring the change of temperature at each temperature sensor, calculating the energy for the corresponding volume for each sensor, and summing the energy changes for all the sensors to determine the amount of energy consumed. The energy usage can be recorded with chronological information to construct a usage pattern which can be used for controlling the heater and for providing the user with details of energy usage. The system does not require the use of data derived from a flow meter.

Abstract: A method of measuring the amount of energy consumed from a water heater having a tank with two or more temperature sensors located a predetermined heights on or in the tank, the method including the step of; for each sensor, determining a corresponding volume of a segment of the tank, measuring the change of temperature at each temperature sensor, calculating the energy for the corresponding volume for each sensor, and summing the energy changes for all the sensors to determine the amount of energy consumed. The energy usage can be recorded with chronological information to construct a usage pattern which can be used for controlling the heater and for providing the user with details of energy usage. The system does not require the use of data derived from a flow meter.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: Disclosed are compounds having [1,2,4]triazolo[4,3-a]pyridine groups and pharmaceutically acceptable salts thereof. The compounds are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Abstract: Compounds of formula (I) are inhibitors of neutrophil elastase, wherein A is C—R1 or N; —X1—X2— is CR15?N— or —NR19—CO—; and R1-R6, R15, R15 and R19 are as defined in the claims.

Abstract: Compounds of formula (I) are inhibitors of neutrophil elastase, wherein A is C—R1 or N; —X1—X2— is CR15?N— or —NR19—CO—; and R1-R6, R15 and R16 are as defined in the claims.

Abstract: There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.

Abstract: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.

Abstract: Disclosed are compounds having [1,2,4]triazolo[4,3-a]pyridine groups and pharmaceutically acceptable salts thereof. The compounds are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

Abstract: The subject invention provides compounds of formula (I): Including monomers and multimers thereof that are inhibitors of human neutrophil elastase (HNE) activity and are useful in the treatment of diseases or conditions in which HNE plays a part.

Abstract: A method of measuring the amount of energy consumed from a water heater having a tank with two or more temperature sensors located a predetermined heights on or in the tank, the method including the step of; for each sensor, determining a corresponding volume of a segment of the tank, measuring the change of temperature at each temperature sensor, calculating the energy for the corresponding volume for each sensor, and summing the energy changes for all the sensors to determine the amount of energy consumed. The energy usage can be recorded with chronological information to construct a usage pattern which can be used for controlling the heater and for providing the user with details of energy usage. The system does not require the use of data derived from a flow meter.

Abstract: A pharmaceutical composition adapted for pulmonary administration by inhalation is described, wherein the composition comprises a glitazone and one or more pharmaceutically acceptable carriers and/or excipients, wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer, and wherein the glitazone is pioglitazone or rosiglitazone or a pharmaceutically acceptable salt thereof, and wherein the glitazone is in the form of microparticles.

Abstract: There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.